3/21
01:31 am
anro
Medium
Report
3/18
09:17 am
anro
Alto Neuroscience (ANRO) had its price target raised by Robert W. Baird from $22.00 to $41.00. They now have an "outperform" rating on the stock.
Low
Report
Alto Neuroscience (ANRO) had its price target raised by Robert W. Baird from $22.00 to $41.00. They now have an "outperform" rating on the stock.
3/17
08:43 am
anro
Alto Neuroscience (ANRO) had its "buy" rating reaffirmed by Chardan Capital. They now have a $30.00 price target on the stock.
Medium
Report
Alto Neuroscience (ANRO) had its "buy" rating reaffirmed by Chardan Capital. They now have a $30.00 price target on the stock.
3/17
08:43 am
anro
Alto Neuroscience (ANRO) had its price target raised by Wedbush from $13.00 to $22.00. They now have a "neutral" rating on the stock.
Medium
Report
Alto Neuroscience (ANRO) had its price target raised by Wedbush from $13.00 to $22.00. They now have a "neutral" rating on the stock.
3/16
12:08 pm
anro
Alto Neuroscience (ANRO) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
Low
Report
Alto Neuroscience (ANRO) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
3/16
07:51 am
anro
Alto Neuroscience announces $120M private placement financing [Seeking Alpha]
Medium
Report
Alto Neuroscience announces $120M private placement financing [Seeking Alpha]
3/16
07:40 am
anro
Alto Neuroscience Announces $120 Million Private Placement Financing [Yahoo! Finance]
Low
Report
Alto Neuroscience Announces $120 Million Private Placement Financing [Yahoo! Finance]
3/16
07:03 am
anro
Alto Neuroscience Announces $120 Million Private Placement Financing
Medium
Report
Alto Neuroscience Announces $120 Million Private Placement Financing
3/16
06:23 am
anro
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights [Yahoo! Finance]
Medium
Report
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights [Yahoo! Finance]
3/16
06:14 am
anro
Alto Neuroscience GAAP EPS of -$2.19 beats by $0.06 [Seeking Alpha]
Medium
Report
Alto Neuroscience GAAP EPS of -$2.19 beats by $0.06 [Seeking Alpha]
3/16
06:03 am
anro
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights
Medium
Report
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights
3/13
08:03 am
anro
Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum
Low
Report
Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum
2/23
08:33 am
anro
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
Medium
Report
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
2/17
08:02 am
anro
Alto Neuroscience (NYSE:ANRO) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $28.00 price target on the stock, up previously from $27.00.
High
Report
Alto Neuroscience (NYSE:ANRO) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $28.00 price target on the stock, up previously from $27.00.
2/13
08:04 am
anro
Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia
Low
Report
Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia
2/3
08:54 am
anro
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment [Yahoo! Finance]
Low
Report
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment [Yahoo! Finance]
2/3
08:27 am
anro
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment
Low
Report
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment
1/20
09:31 am
anro
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Alto Neuroscience, Inc. (ANRO), Atkore Inc. (ATKR), Replimune Group, Inc. (REPL), and Fly-E Group, Inc. (FLYE)
Medium
Report
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Alto Neuroscience, Inc. (ANRO), Atkore Inc. (ATKR), Replimune Group, Inc. (REPL), and Fly-E Group, Inc. (FLYE)
1/14
07:51 am
anro
Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression [Yahoo! Finance]
Medium
Report
Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression [Yahoo! Finance]
1/14
07:27 am
anro
Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression
Low
Report
Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression
1/14
03:53 am
anro
Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology [Yahoo! Finance]
Low
Report
Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology [Yahoo! Finance]
1/13
08:00 am
anro
Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology
Medium
Report
Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology
1/5
08:33 am
anro
Alto Neuroscience (NYSE:ANRO) had its price target raised by analysts at Chardan Capital from $15.00 to $30.00. They now have a "buy" rating on the stock.
Low
Report
Alto Neuroscience (NYSE:ANRO) had its price target raised by analysts at Chardan Capital from $15.00 to $30.00. They now have a "buy" rating on the stock.
12/26
08:57 am
anro
Alto Neuroscience, Inc. (NYSE:ANRO) is definitely on the radar of institutional investors who own 33% of the company [Yahoo! Finance]
Medium
Report
Alto Neuroscience, Inc. (NYSE:ANRO) is definitely on the radar of institutional investors who own 33% of the company [Yahoo! Finance]